Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.
Press releases published on June 2, 2025
Denodo University Challenge Now Open: Data and AI for Real-World Impact
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Denodo, a leader in data management, announced that the Denodo Academic Program, which prepares students to become future leaders in the field of data and analytics, has opened registration for the next …
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
GlobeNewswire
·
June 2, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical …
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
GlobeNewswire
·
June 2, 2025
Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all …
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
GlobeNewswire
·
June 2, 2025
– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory markers …
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director Slate
GlobeNewswire
·
June 2, 2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder …
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
GlobeNewswire
·
June 2, 2025
Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide …
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
GlobeNewswire
·
June 2, 2025
- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - WAYNE, Pa., June …
SAIC Announces First Quarter of Fiscal Year 2026 Results
GlobeNewswire
·
June 2, 2025
Revenues of $1.88 billion; approximately 2% revenue growth Net bookings of $2.4 billion; book-to-bill ratio of 1.3 Net income of $68 million; Adjusted EBITDA(1) of $157 million or 8.4% of revenues Diluted earnings per share of $1.42; Adjusted diluted …
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
GlobeNewswire
·
June 2, 2025
Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio …
BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt
GlobeNewswire
·
June 2, 2025
BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard zu setzen, der über die traditionellen …
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
GlobeNewswire
·
June 2, 2025
BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types The co- …
Brazil Potash Year to Date Summary: Company Achieves Milestones, Advancing Strategic Autazes Project Further Towards Construction
GlobeNewswire
·
June 2, 2025
Achievements Include Commercial Agreements, World-Class Board Appointments, Construction Progress, and Enhanced Capital Access Management to Attend Wells Fargo Industrials Conference on June 10, 2025, in Chicago MANAUS, Brazil, June 02, 2025 (GLOBE …
Resumo do Ano da Brazil Potash: Empresa Alcança Marcos Importantes, Avançando o Projeto Estratégico Autazes em Direção à Construção
GlobeNewswire
·
June 2, 2025
Conquistas Incluem Acordos Comerciais, Nomeações de Classe Mundial para o Conselho, Progresso na Construção e Acesso Aprimorado ao Capital Administração Participará da Conferência Industrial Wells Fargo em 10 de Junho de 2025, em Chicago MANAUS, Brasil, …
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
GlobeNewswire
·
June 2, 2025
YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial …
L’hébergement souverain : un impératif stratégique
GlobeNewswire
·
June 2, 2025
Le contexte géopolitique actuel est plus que jamais un signal fort sur la nécessité de repenser nos infrastructures IT et de positionner la souveraineté comme un enjeu central. En effet, au cœur de la création de valeur des entreprises, le numérique est un …
ClarityCut AI Launches to Revolutionize Video Editing with AI-Powered Simplicity
GlobeNewswire
·
June 2, 2025
SEATTLE, June 02, 2025 (GLOBE NEWSWIRE) -- CLEANZONE HVAC LLC proudly announces the official launch of ClarityCut AI, a cutting-edge video editing platform designed to empower creators through the speed and precision of artificial intelligence. The …
Conscio Technologies lance une offre de sensibilisation à la cybersécurité dédiée aux professionnels de l’assurance
GlobeNewswire
·
June 2, 2025
Conscio Technologies, spécialiste de la sensibilisation à la cybersécurité, annonce la création d’une offre dédiée aux acteurs de l’assurance et notamment la mise à disposition d’un contenu spécifique sur la réglementation DORA. Le secteur des assurances …
Xilio Therapeutics Announces Proposed Public Offering
GlobeNewswire
·
June 2, 2025
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is …
IA génératives : reprendre la main, la vision de SASETY pour les entreprises
GlobeNewswire
·
June 2, 2025
Par Jérôme Beaufils, CEO de SASETY Introduction Les intelligences artificielles génératives transforment rapidement les usages professionnels. Génération de contenu, assistance au code, automatisation de tâches : leur potentiel est immense. Mais leur …
Curevo Enrolls First Participants in Phase 2 Extension Trial
GlobeNewswire
·
June 2, 2025
SEATTLE, June 02, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the enrollment of the first …